FDA Issues Draft Guidance on Electronic Submission Template for PMAs in 2026, Comments Due November 17

FDA Issues Draft Guidance on Electronic Submission Template for PMAs

On September 18, 2026, the U.S. Food and Drug Administration (FDA) released a draft guidance titled Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs). On the same day, the Federal Register published an availability notice under Docket No. FDA-2026-D-9429. Comments are due by November 17, 2026.

The draft guidance is intended for sponsors submitting PMAs and certain PMA supplements to the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER). It introduces currently available electronic submission resources and related materials, with the goal of improving consistency in submissions and enhancing review efficiency. The draft is explicitly not for implementation at this stage; further standards for electronic format, a timeline for their establishment, and criteria for exemptions and exceptions will be provided only after the guidance is finalized.

Positioning of the Draft Guidance

The draft refers to the electronic submission template as a guided submission preparation tool. FDA explains that such templates are developed to improve the consistency of submissions and increase the efficiency of the review process. This draft is one in a series of steps to introduce submitters to already publicly available electronic submission resources and related content. The document is clearly marked as a draft, not for implementation, and will only provide further standards for electronic format, a timeline for standard development, and criteria for exemptions and exceptions upon finalization.

Scope and Boundaries

The draft applies to submitters of PMAs and certain PMA supplements, with CDRH and CBER as the receiving centers. The document also addresses the legal basis: Section 745A(b)(3) of the Federal Food, Drug, and Cosmetic Act authorizes FDA to require certain submissions to be submitted in a specified electronic format. It is important to note that the draft does not change current requirements, nor is it an immediately effective obligation; it is better understood as a directional signal for future submission formats.

Comment Window

The Federal Register availability notice states that electronic or written comments on the draft should be submitted by November 17, 2026, for FDA to consider before drafting the final version. Comments should be submitted via regulations.gov and must reference Docket No. FDA-2026-D-9429.

Context Within Electronic Submission Initiatives

Electronic submission templates are not an entirely new topic. FDA previously issued a similar guidance for 510(k) electronic submission templates (October 2023) and operates programs such as eCopy for electronic copies. For PMAs, the focus has historically been on electronic copy requirements. This draft extends the template and structured approach to PMAs and certain supplements, continuing the same direction. For companies that have pursued or plan to pursue the PMA pathway, this signals that expectations for document organization are becoming more unified.

Sources

• U.S. Food and Drug Administration (FDA) – CDRH/CBER, Electronic Submission Template for Premarket Approval Applications (PMA), Draft Guidance, September 18, 2026.
• Federal Register, Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availability, September 18, 2026 (91 FR 59139).
• FDA guidance PDF and Docket No. FDA-2026-D-9429.
• Verification scope and access date: FDA guidance page (title, publication month, docket number, issuing centers, draft status), Federal Register availability notice (publication date, comment deadline, docket number, legal basis), and first page of the draft guidance PDF were verified. Access date: September 30, 2026 (Asia/Shanghai).

Applicability note: This article is an interpretation of publicly available FDA regulatory information and does not constitute a conclusion or commitment for any specific product, company, or registration application. The draft is non-binding and not for implementation; final standards, timelines, and exemption criteria are subject to FDA's final text. Information may change with subsequent official updates.

AIMEILI Regulatory Interpretation

From a regulatory affairs perspective, this draft guidance signals FDA's continued movement toward structured electronic submissions for high-risk device applications. While the draft is not immediately effective, it is a clear indicator that PMA submissions will increasingly be expected to follow standardized electronic templates. The legal basis under Section 745A(b)(3) provides FDA with the authority to mandate electronic formats, so sponsors should anticipate that future requirements may become binding. The phased approach—draft, comment period, finalization, and then implementation standards—gives industry an opportunity to provide feedback and prepare. The explicit mention of exemptions and exceptions suggests FDA recognizes that certain submissions may face practical challenges, but the criteria for such exceptions will not be known until finalization. Companies should monitor the docket and consider participating in the comment process to shape the final requirements.

Business Impact

For medical device manufacturers, distributors, CROs, and regulatory affairs teams, this draft guidance has several practical implications:

• Preparation for electronic templates: Companies with PMAs or PMA supplements in the pipeline should begin assessing their current document organization and submission processes to align with future template requirements. Early adoption can reduce rework and streamline review.
• Resource allocation: Investing in electronic submission tools and training may be necessary. Regulatory teams should budget for potential changes in submission software and internal workflows.
• Comment opportunity: The comment period until November 17, 2026, is a chance to influence the final guidance. Stakeholders can provide feedback on practical challenges, propose timelines, and suggest exemption criteria.
• Global harmonization: As FDA moves toward structured electronic submissions, other regulatory authorities may follow. Companies should consider harmonizing their electronic submission strategies across regions to gain efficiencies.
• Competitive advantage: Early compliance with electronic submission templates can position companies favorably with FDA, potentially leading to faster review times and smoother interactions.

Overall, while the draft is not yet enforceable, it represents a strategic shift that warrants attention and proactive planning. AIMEILI will continue to monitor developments and provide updates as the guidance progresses.